JPW

Dkt. 51917-CB-PCT-US/JPW/AJM/AAB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: David J. Pinsky et al.

Serial No.: 10/692,439

Filed : October 22, 2003

For : METHODS FOR TREATING ISCHEMIC DISORDER AND IMPROVING STROKE OUTCOME

1185 Avenue of the Americas
New York, New York 10036
June 15, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, applicants would like to direct the Examiner's attention to the following publications which are listed on the attached Form PTO-1449 (**Exhibit A**). Copies of cited publications 16, 28 and 41 are attached hereto as **Exhibits 1-3** respectively. Publications 26, 45, 48-53, 55, 60-62, 64, 67, 69, 70, 72, 73, 80, 81 and 84 are of record in prior application U.S. Serial No. 08/721,447, filed September 27, 1996, to which priority under 35 U.S.C. §120 is claimed. Publications 1 and 47 are of record in prior application U.S. Serial No. 09/053,871 filed April 1, 1998, to which priority under 35 U.S.C. §120 is claimed. Publications 2-15, 17-25, 27, 29-40, 42-44, 46, 54, 56-59, 63, 65, 66, 68, 71, 74-79, 82, 83, 85 and 86 are of record in prior application U.S. Serial No. 09/671,100, filed

September 27, 2000, to which priority under 35 U.S.C. §120 is claimed. According to 37 C.F.R. §1.98(d), copies of patents or publications that are of record in such prior applications need not accompany this Information Disclosure Statement.

1. U.S. Patent No. 4,711,848, Insley et al., Site Specific Mutagenesis in Alpha-1-Antitrypsin, issued December 8, 1987.

2. U.S. Patent No. 4,885,277, Nawroth, Anticoagulant therapy, issued December 5, 1989.

3. U.S. Patent No. 5,169,786, Carroll et al., Method of determining levels of extrinsic and intrinsic clotting factors and protein C, issued December 8, 1992.

4. U.S. Patent No. 5,378,464, McEver, Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140, issued January 3, 1995.

5. U.S. Patent No. 5,443,960, Dahlback, Method for the diagnosis of blood coagulation disorders, issued August 22, 1995.

6. U.S. Patent No. 5,472,850, Morrisey, Quantitative clotting assay for activated factor VII, issued December 5, 1995.

7. U.S. Patent No. 5,498,601, Sato et al., Platelet aggregation-inhibiting peptides, issued March 12, 1996.

8. U.S. Patent No. 5,602,233, King, Process for production of inhibited forms of activated blood factors, issued February 11, 1995.

9. U.S. Patent No. 5,618,788, Capon et al., Preparation of functional human factor VIII and pharmaceutical treatment therewith, issued April 8, 1997.

10. U.S. Patent No. 5,807,980, Lasters et al., Bovine pancreatic trypsin inhibitor derived inhibitors of factor VIIa-tissue factor complex, issued September 15, 1998.

11. U.S. Patent No. 5,839,443, Rose et al., Method for Inhibiting Thrombosis in a Patient Whose Blood is Subjected to Extracorporeal Circulation, issued November 24, 1998.

12. U.S. Patent No. 5,962,266, White et al., Protease inhibitor peptides, issued October 5, 1999.

13. U.S. Patent No. 6,315,995 B1, Pinsky et al., Method for Treating an Ischemic Disorder and Improving Stroke Outcome, issued November 13, 2001.

14. U.S. Patent No. 6,316,403 B1, Pinsky et al., Method for Treating an Ischemic Disorder and Improving Stroke Outcome, issued November 13, 2001.

15. U.S. Patent No. 6,391,300, Rose et al., Method for Inhibiting Thrombosis in a Patient Whose Blood is Subjected to Extracorporeal Circulation, issued May 21,

2002.

16. WO 94/05314A, Peptide Inhibitors of Leukocyte Adhesion, Centocor Inc., March 17, 1994 **(Exhibit 1)**.

17. PCT International Application No. WO 94/22885, Kisilvesky et al., Queens University, Anticoagulant Compounds, published October 13, 1994.

18. WO 95/17421, Peptide Analogs of the Factor Ixa Platelet Binding Site, Walsh et al., Temple University, June 29, 1995.

19. WO 95/34319, Compositions and Methods for the Treatment of Tumours, Vehar Gordon, Genentech Inc (US), December 21, 1995.

20. WO 96/00577, Agents Affecting Thrombosis Hemostasis, Sinha et al., COR THERAPEUTICS INC (US), January 11, 1996.

21. WO 97/42900, Trustees of Columbia University, Rose et al., Method for Inhibiting Thrombosis in a Patient Whose Blood is Subjected to Extracorporeal Circulation, published November 20, 1997; filed May 15, 1997.

22. WO 98/13058, Trustees of Columbia University, Pinsky et al., Method for Treating an Ischemic Disorder and Improving Stroke Outcome, published April 2, 1998; filed September 25, 1997.

23. WO 99/49803, Trustees of Columbia University, Rose et al., Method for Inhibiting Thrombosis in a Patient Whose Blood is Subjected to Extracorporeal Circulation, published October 7, 1999; filed April 1, 1999.

24. WO 99/49880, Trustees of Columbia University, Pinsky et al., Method for Treating an Ischemic Disorder and Improving Stroke Outcome, published October 7, 1999; filed April 1, 1999.

25. Australian Patent No. 735258, Trustees of Columbia University, Rose et al., Method for Inhibiting Thrombosis in a Patient Whose Blood is Subjected to Extracorporeal Circulation, issued July 5, 2001.

26. Canadian Patent No. 2,141,642, Moeller, et al. Platelet-Stabilising Factor IX Fragments, the Preparation Thereof and Pharmaceutical Compositions Containing Them, issued March 8, 1995.

27. U.S. Serial No. 09/053,872, Rose et al., Method for Inhibiting Thrombosis in a Patient Whose Blood is Subjected to Extracorporeal Circulation, filed April 1, 1998.

28. U.S. Serial No. 10/679,135, Pinsky et al., Methods for Teating Ischemic Disorders Using Carbon Monoxide, filed October 3, 2003.

29. International Search Report August 29, 1997 for PCT/US97/08282.

30. International Preliminary Examination, April 20, 1998 for PCT/US97/08282.

31. Search Report October 27, 2000 from Patent Office regarding European Patent Application No. 97926541.0.

32. International Search Report, June 18, 1999 for PCT/US99/07173.

33. International Preliminary Examination, January 7, 2000 for PCT/US99/07173.

34. Search Report, May 28, 2002 from Patent Office regarding European Patent Application No. 99916264.7.

35. International Search Report, February 5, 1998 for PCT/US97/17229.

36. Written Opinion September 14, 1998 for PCT/US97/17229.

37. International Preliminary Examination, January 8, 1999 for PCT/US97/17229.

38. International Search Report, August 4, 1999 for PCT/US99/07175.

39. Written Opinion, February 3, 2000 for PCT/US99/07175.

40. International Preliminary Examination, July 11, 2000 for PCT/US99/07175.

41. Partial European Search Report, March 1, 2004 from European Patent Office on European Patent Application No. EP 97944453.6 **(Exhibit 3)**.

42. Bajaj et al. (1992) Antibody-probed conformational transitions in the protease domain of human factor IX upon calcium binding and zymogen activation: putative high-affinity Ca(2+)-binding site in the protease domain. Proc. Natl. Acad. Sci. USA 89:152-156.

43. Bazan, J.F. (1996) Big Rigs in Blood Coagulation. Nature 380:21-23.

44. Benedict C.R. et al. (1991) Active Site-Blocked Factor IXa Prevents Intravascular Thrombus Formation in the Coronary Vasculature Without Inhibiting Extravascular Coagulation in a Canine Thrombosis Model. J. Clin. Invest. 88:1760-1765.

45. Benedict C.R., et al. (1994) Endothelial-Dependent Procoagulant and Anticoagulant Mechanisms, Recent Advances in Understanding. Texas Heart Institute Journal 21:86-90.

46. Berntorp, E. (1993) Biochemical and In Vivo Properties of High Purity Factor IX Concentrates. Thrombosis and Haemostasis. 70:768-773.

47. Brandstetter et al. (1995) X-ray structure of clotting Factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc. Natl. Acad. Sci. U.S.A. 92:9796-800.

48. Bronner et al. (1995) Primary prevention of stroke. The New England J. Med. 333:1392-1400.

49. Brown and Piantadosi (1992) Recovery of Energy Metabolism in Rat After Carbon Monoxide Hypoxia. J. Clin. Invest. 89:666-672.

50. Carlos and Harlan (1994) Leukocyte-Endothelial Adhesion Molecules. Blood. 24:2068-2102.

51. Connolly et al. (1996) Cerebral Protection in Homozygous Null ICAM-1 Mice After Middle Cerebral Artery Occlusion. J. Clin. Invest. 97:209-216.

52. Connolly et al. (1996) Procedural and Strain-Related Variables Significantly Affect Outcome in a Murine Model of Focal Cerebral Ischemia. Neurosurgery. 38:523-532.

53. Dawson and Synder (1994) Gases as Biological Messengers: Nitric Oxide and Carbon Monoxide in the Brain, J. Neurosci. 14, 5147-5159.

54. Dietrich et al. (1995) Influence of High-Dose Aprotinin on Anticoagulation, Heparin Requirement, and Celite-and Kaolin-Activated Clotting Tie in Heparin-pretreated Patients Undergoing Open-Heart Surgery. Anesthesiology, 83(4)679-689.

55. Fassbender et al. (1995) Circulating Selectin-and Immunoglobin-Type Adhesion Molecules in Acute Ischemic

Stroke. Stroke. 26:1361-1364.

56. Freedman, S.J. et al., (1995) Structure of the Metal-Free γ-Carboxy-glumatic Acid-Rich Membrane Binding Region of Factor IX Two-dimensional NMR Spectroscopy. J. Biol. Chem. 270:7980-7987.

57. Furie, B.C. and Furie, B. (1995) Biosynthesis of Factor IX: Implications for Gene Therapy. Thrombosis and Haemostasis 74:274-277.

58. Holdright, D., et al. (1994) Comparison of the Effect of Heparin and Aspirin Versus Aspirin Alone on Transient Myocardial Ischemia and In-hospital Prognosis in Patients With Unstable Angina. J. Am. Coll. Cardiol. 24:39-45.

59. Iberti, T.J. et al., (1994) Abnormal Coagulation Profile in Brain Tumor Patients During Surgery. Neurosurgery 34:389-395.

60. Ishimaru et al. (1991) Effects of Successive Carbon Monoxide Exposure on Delayed Neuronal Death in Mice Under the Maintenance of Normal Body Temperature, Biochem. Biophys. Res. Commun. 179, 836-840.

61. Jerome et al. (1994) P-selectin and ICAM-1-Dependent Adherence Reactions: Role in the Genesis of Postischemic No-Reflow. Am. J. Physiol. 226:H1316-H1321.

62. Kim et al. (1995) Adhesive Glycoproteins CD11a and

Cd18 are Upregulated in the Leukocytes from Patients with Ischemic Stroke and Transient Ischemic Attacks. J. Neurol. Sci. 128:45-50.

63. Kirchhofer, Daniel et al. (1995) Active Site-Blocked Factors VIIa and IXa Differentially Inhibit Fibrin Formation in a Human Ex Vivo Thrombosis Model. Arterioscler. Thromb. Vasc. Biol. 15:1098-1106.

64. Kochaneck and Hallenbeck (1992) Polymorphonuclear Leukocytes and Monocytes/Macrophages in the Pathogenesis of Cerebral Ischemia and Stroke. Stroke. 23:1367-1379.

65. Kuwabara, K. et al., (1995) Calreticulin, an Antithrombotic Agent which Binds to Vitamin K-Dependent Coagulation Factors, Stimulates Endothelial Nitric Oxide Production, and Limits Thrombosis in Canine Coronary Arteries. J. Biol. Chem. 270:8179-8187.

66. Lenting et al. (1995) Cleavage at Arginine 145 in Human Blood Coagulation Factor IX Converts the Zymogen into a Factor VIII Binding Enzyme. J. Biol. Chem. 270(25):14884-14890.

67. Mayevsky et al. (1995) Multiparametric Monitoring of the Awake Brain Exposed to Carbon Monoxide, J. Appl. Physiol. 78, 1188-1196.

68. Miyata, T. et al., (1994) Factor IX Bm Kiryu: A Val-313-to-Asp Substitution in the Catalytic Domain

Results in Loss of Function Due to a Conformational Change of the Surface Loop: Evidence Obtained by Chimeric Modeling. Brit. J. Haematol. 88:156-165.

69. Okada et al. (1994) P-selectin and Intercellular Adhesion Molecule-1 Expression After Focal Brain Ischemia and Reperfusion. Stroke. 25:202-211.

70. Pinsky et al. (1996) Hypoxia-Induced Exocytosis of Endothelial Cell Weibel-Palade Bodies, a Mechanism for Rapid Neutrophil Recruitment After Cardiac Preservation. J. Clin. Invest. 97:493-500.

71. Santagostino, E. et al., (1994) Markers of Hypercoagulability in Patients with Hemophilia B Given Repeated, Large Doses of Factor IX Concentrates During and After Surgery. Thrombosis and Haemostasis 71: 737-740.

72. Schroeter et al. (1994) Local Immune Response in the Rat Cerebral Cortex After Middle Cerebral Artery Occlusion. J. Neuroimmunol. 55:195-203.

73. Seekamp et al. (1994) Role of Selectins in Local and Remote Tissue Injury Following Ischemia and Reperfusion. Am. J. Pathol. 44:592-598.

74. Spanier et al., (1997) Active-Site Blocked Factor IXa is a Selective Alternative Anticoagulant to Heparin in Cardiopulmonary Bypass. Circulation. 96:1672.

75. Spanier et al., (1997) Active Site-Blocked Factor IXa

(IXai): A Novel Selective Anticoagulant for Use in Cardiopulmonary Bypass. Surgical Forum. 48:259-261.

76. Spanier et al., (1997) Selective Anticoagulation with Active Site Blocked Factor IXa in Synthetic Patch Vascular Repair Results in Decreased Blood Loss and Operative Time. ASAIO J. 43:M526-M530.

77. Spanier et al., (1998) A Novel Anticoagulant Strategy in Peripheral Vascular Surgery that Decreases Operative Blood Loss. Surgical Forum. 49:333-335.

78. Spanier et al., (1998) Heparinless Cardiopulmonary Bypass with Active-Site Blocked Factor IXa: A Preliminary Study on the Dog. J. Thorac. Cardiovasc. Surg. 115(5):1179-1188.

79. Spanier et al., (1998) Selective Anticoagulation with Active Site-Blocked Factor IXa Suggests Separate Roles for Intrinsic and Extrinsic Coagulation Pathways in Cardiopulmonary Bypass. J. Thorac. Cardiovasc. Surg. 116(5):860-890.

80. Tijburg et al., (1991) Activation of the coagulation mechanism on tumor necrosis factor-stimulated cultured endothelial cells and their extracellular matrix. The role of flow and Factor IX/IXa. J. Biol. Chem. 266:12067-12074.

81. Verma et al. (1993) Carbon Monoxide: a Putative Neural Messenger, Science 259, 381-384.

82. Wacey, A.I. et al., (1994) Determinants of the Factor IX Mutational Spectrum in Hemophilia B: An Analysis if Missense Using A Multi-Domain Molecular Model of the Activated Protein. Hum. Genet. 94:594-608.

83. Warrier, I. et al., (1995) Safety of High Doses of Monoclonal Antibody Purified Factor IX Concentrate. Am. J. of Hematol. 49:92-94.

84. Weyrich et al. (1993) In Vivo Neutralization of P-selectin Protects Feline Heart Endothelium in Myocardial Ishchemia and Reperfusion Injury. J. Clin. Invest. 91:2620-2629.

85. Wong, A.G. et al., (1995) Relative Efficacy of Active Site-Blocked Factors IXa in a Model of Venous Thrombosis. Circulation. 92:I-686 (Abstract # 3293).

86. Wyngaarden et al. Ceril Textbook of Medicine, 19th Edition, Phil.: W.B. Saunders Company, Vol. 2:2376.

Pursuant to 37 C.F.R. §1.97(b)(3) no fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. No. (212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

6/15/04

Alan J. Morrison Date
Reg. No. 37,399

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 51917-CB-PCT-US/ JPW/AJM/AAB	Serial No. 10/692,439
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: David J. Pinsky et al.	
	Filing Date October 22, 2003	Group

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
		4 7 1 1 8 4 8	12/8/1987	Insley et al.	435	69.2	
		4 8 8 5 2 7 7	12/5/1989	Nawroth	514	15	
		5 1 6 9 7 8 6	12/8/1992	Carroll et al.	436	69	
		5 3 7 8 4 6 4	1/3/1995	McEver	424	143.1	
		5 4 4 3 9 6 0	8/22/1995	Dahlback	435	13	
		5 4 7 2 8 5 0	12/5/1995	Morrisey	435	13	
		5 4 9 8 6 0 1	03/12/1996	Sato et al.	514	17	
		5 6 0 2 2 3 3	2/11/1995	King	530	381	
		5 6 1 8 7 8 8	4/8/1997	Capon et al.	514	12	
		5 8 0 7 9 8 0	4/8/1997	Lasters et al.			
		5 8 3 9 4 4 3	11/24/1998	Rose et al.	128	898	
		5 9 6 2 2 6 6	10/5/1999	White et al.	435	692	
		6 3 1 5 9 9 5	11/13/2001	Pinsky et al.	424	94.63	
		6 3 1 6 4 0 3	11/13/2001	Pinsky et al.	514	2	
		6 3 9 1 3 0 0	5/21/2002	Rose et al.	424	145.1	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
		9 4 0 5 3 1 4A	3/17/1994	WO (Exhibit 1)				
		9 4 2 2 8 8 5	10/13/1994	WO				
		9 5 1 7 4 2 1	6/29/1995	WO				
		9 5 3 4 3 1 9	12/21/1995	WO				
		9 6 0 0 5 7 7	1/11/1996	WO				
		9 7 4 2 9 0 0	11/20/1997	WO				
		9 8 1 3 0 5 8	4/2/1998	WO				
		9 9 4 9 8 0 3	10/7/1999	WO				
		9 9 4 9 8 8 0	10/7/1999	WO				
		7 3 5 2 5 8	11/20/1997	AU				
		2 1 4 1 6 4 2	3/8/1995	CA				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		U.S. Serial No. 09/053,872, Rose et al., Method for Inhibiting Thrombosis in a Patient Whose Blood is Subjected to Extracorporeal Circulation, filed April 1, 1998.
		U.S. Serial No. 10/679,135, Pinsky et al., Methods for Treating Ischemic Disorders Using Carbon Monoxide, filed October 3, 2003 (**Exhibit 2**)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 51917-CB-PCT-US/ JPW/AJM/AAB	Serial No. 10/692,439
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: David J. Pinsky et al.	
	Filing Date October 22, 2003	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		International Search Report, August 29, 1997 for PCT/US97/08282.
		International Preliminary Examination, April 20, 1998 for PCT/US97/08282.
		Search Report October 27, 2000 from Patent Office regarding European Patent Application No. 97926541.0.
		International Search Report, June 18, 1999 for PCT/US99/07173.
		International Preliminary Examination, January 7, 2000 for PCT/US99/07173.
		Search Report, May 28, 2002 from Patent Office regarding European Patent Application No. 99916264.7.
		International Search Report, February 5, 1998 for PCT/US97/17229.
		Written Opinion September 14, 1998 for PCT/US97/17229.
		International Preliminary Examination, January 8, 1999 for PCT/US97/17229.
		International Search Report, August 4, 1999 for PCT/US99/07175.
		Written Opinion February 3, 2000 for PCT/US99/07175.
		International Preliminary Examination, July 11, 2000 for PCT/US99/07175.
		Partial European Search Report, March 1, 2004 from European Patent Office on European Patent Application No. EP 97944453.6 **(Exhibit 3)**.
		Bajaj et al. (1992) Antibody-probed conformational transitions in the protease domain of human factor IX upon calcium binding and zymogen activation: putative high-affinity Ca(2+)-binding site in the protease domain. Proc. Natl. Acad. Sci. USA 89:152-156.
		Bazan, J.F. (1996) Big Rigs in Blood Coagulation. Nature 380:21-23.

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 51917-CB-PCT-US/ JPW/AJM/AAB	Serial No. 10/692,439
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: David J. Pinsky et al.	
	Filing Date October 22, 2003	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Benedict C.R. et al. (1991) Active Site-Blocked Factor IXa Prevents Intravascular Thrombus Formation in the Coronary Vasculature Without Inhibiting Extravascular Coagulation in a Canine Thrombosis Model. J. Clin. Invest. 88:1760-1765.
		Benedict C.R., et al. (1994) Endothelial-Dependent Procoagulant and Anticoagulant Mechanisms, Recent Advances in Understanding. Texas Heart Institute Journal 21:86-90.
		Berntorp, E. (1993) Biochemical and In Vivo Properties of High Purity Factor IX Concentrates. Thrombosis and Haemostasis. 70:768-773.
		Brandstetter et al. (1995) X-ray structure of clotting Factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc. Natl. Acad. Sci. U.S.A. 92:9796-800.
		Bronner et al. (1995) Primary prevention of stroke. The New England J. Med. 333:1392-1400.
		Brown and Piantadosi (1992) Recovery of Energy Metabolism in Rat After Carbon Monoxide Hypoxia. J. Clin. Invest. 89:666-672.
		Carlos and Harlan (1994) Leukocyte-Endothelial Adhesion Molecules. Blood. 24:2068-2102.
		Connolly et al. (1996) Cerebral Protection in Homozygous Null ICAM-1 Mice After Middle Cerebral Artery Occlusion. J. Clin. Invest. 97:209-216.
		Connolly et al. (1996) Procedural and Strain-Related Variables Significantly Affect Outcome in a Murine Model of Focal Cerebral Ischemia. Neurosurgery. 38:523-532.
		Dawson and Synder (1994) Gases as Biological Messengers: Nitric Oxide and Carbon Monoxide in the Brain, J. Neurosci. 14, 5147-5159.
		Dietrich et al. (1995) Influence of High-Dose Aprotinin on Anticoagulation, Heparin Requirement, and Celite-and Kaolin-Activated Clotting Tie in Heparin-pretreated Patients Undergoing Open-Heart Surgery. Anesthesiology, 83(4)679-689.

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 51917-CB-PCT-US/ JPW/AJM/AAB	Serial No. 10/692,439
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: David J. Pinsky et al.	
	Filing Date October 22, 2003	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Fassbender et al. (1995) Circulating Selectin-and Immunoglobin-Type Adhesion Molecules in Acute Ischemic Stroke. Stroke. 26:1361-1364.
		Freedman, S.J. et al., (1995) Structure of the Metal-Free γ-Carboxy-glumatic Acid-Rich Membrane Binding Region of Factor IX Two-dimensional NMR Spectroscopy. J. Biol. Chem. 270:7980-7987.
		Furie, B.C. and Furie, B. (1995) Biosynthesis of Factor IX: Implications for Gene Therapy. Thrombosis and Haemostasis 74:274-277.
		Holdright, D., et al. (1994) Comparison of the Effect of Heparin and Aspirin Versus Aspirin Alone on Transient Myocardial Ischemia and In-hospital Prognosis in Patients With Unstable Angina. J. Am. Coll. Cardiol. 24:39-45.
		Iberti, T.J. et al., (1994) Abnormal Coagulation Profile in Brain Tumor Patients During Surgery. Neurosurgery 34:389-395.
		Ishimaru et al. (1991) Effects of Successive Carbon Monoxide Exposure on Delayed Neuronal Death in Mice Under the Maintenance of Normal Body Temperature, Biochem. Biophys. Res. Commun. 179, 836-840.
		Jerome et al. (1994) P-selectin and ICAM-1-Dependent Adherence Reactions: Role in the Genesis of Postischemic No-Reflow. Am. J. Physiol. 226:H1316-H1321.
		Kim et al. (1995) Adhesive Glycoproteins CD11a and Cd18 are Upregulated in the Leukocytes from Patients with Ischemic Stroke and Transient Ischemic Attacks. J. Neurol. Sci. 128:45-50.
		Kirchhofer, Daniel et al. (1995) Active Site-Blocked Factors VIIa and IXa Differentially Inhibit Fibrin Formation in a Human Ex Vivo Thrombosis Model. Arterioscler. Thromb. Vasc. Biol. 15:1098-1106.
		Kochaneck and Hallenbeck (1992) Polymorphonuclear Leukocytes and Monocytes/Macrophages in the Pathogenesis of Cerebral Ischemia and Stroke. Stroke. 23:1367-1379.

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 51917-CB-PCT-US/ JPW/AJM/AAB	Serial No. 10/692,439
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: David J. Pinsky et al.	
	Filing Date October 22, 2003	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Kuwabara, K. et al., (1995) Calreticulin, an Antithrombotic Agent which Binds to Vitamin K-Dependent Coagulation Factors, Stimulates Endothelial Nitric Oxide Production, and Limits Thrombosis in Canine Coronary Arteries. J. Biol. Chem. 270:8179-8187.
		Lenting et al. (1995) Cleavage at Arginine 145 in Human Blood Coagulation Factor IX Converts the Zymogen into a Factor VIII Binding Enzyme. J. Biol. Chem. 270(25):14884-14890.
		Mayevsky et al. (1995) Multiparametric Monitoring of the Awake Brain Exposed to Carbon Monoxide, J. Appl. Physiol. 78, 1188-1196.
		Miyata, T. et al., (1994) Factor IX Bm Kiryu: A Val-313-to-Asp Substitution in the Catalytic Domain Results in Loss of Function Due to a Conformational Change of the Surface Loop: Evidence Obtained by Chimeric Modeling. Brit. J. Haematol. 88:156-165.
		Okada et al. (1994) P-selectin and Intercellular Adhesion Molecule-1 Expression After Focal Brain Ischemia and Reperfusion. Stroke. 25:202-211.
		Pinsky et al. (1996) Hypoxia-Induced Exocytosis of Endothelial Cell Weibel-Palade Bodies, a Mechanism for Rapid Neutrophil Recruitment After Cardiac Preservation. J. Clin. Invest. 97:493-500.
		Santagostino, E. et al., (1994) Markers of Hypercoagulability in Patients with Hemophilia B Given Repeated, Large Doses of Factor IX Concentrates During and After Surgery. Thrombosis and Haemostasis 71: 737-740.
		Schroeter et al. (1994) Local Immune Response in the Rat Cerebral Cortex After Middle Cerebral Artery Occlusion. J. Neuroimmunol. 55:195-203.
		Seekamp et al. (1994) Role of Selectins in Local and Remote Tissue Injury Following Ischemia and Reperfusion. Am. J. Pathol. 44:592-598.

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 51917-CB-PCT-US/ JPW/AJM/AAB	Serial No. 10/692,439
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: David J. Pinsky et al.	
	Filing Date October 22, 2003	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Spanier et al., (1997) Active-Site Blocked Factor IXa is a Selective Alternative Anticoagulant to Heparin in Cardiopulmonary Bypass. Circulation. 96:1672.
		Spanier et al., (1997) Active Site-Blocked Factor IXa (IXai): A Novel Selective Anticoagulant for Use in Cardiopulmonary Bypass. Surgical Forum. 48:259-261.
		Spanier et al., (1997) Selective Anticoagulation with Active Site Blocked Factor IXa in Synthetic Patch Vascular Repair Results in Decreased Blood Loss and Operative Time. ASAIO J. 43:M526-M530.
		Spanier et al., (1998) A Novel Anticoagulant Strategy in Peripheral Vascular Surgery that Decreases Operative Blood Loss. Surgical Forum. 49:333-335.
		Spanier et al., (1998) Heparinless Cardiopulmonary Bypass with Active-Site Blocked Factor IXa: A Preliminary Study on the Dog. J. Thorac. Cardiovasc. Surg. 115(5):1179-1188.
		Spanier et al., (1998) Selective Anticoagulation with Active Site-Blocked Factor IXa Suggests Separate Roles for Intrinsic and Extrinsic Coagulation Pathways in Cardiopulmonary Bypass. J. Thorac. Cardiovasc. Surg. 116(5):860-890.
		Tijburg et al., (1991) Activation of the coagulation mechanism on tumor necrosis factor-stimulated cultured endothelial cells and their extracellular matrix. The role of flow and Factor IX/IXa. J. Biol. Chem. 266:12067-12074.
		Verma et al. (1993) Carbon Monoxide: a Putative Neural Messenger, Science 259, 381-384.
		Wacey, A.I. et al., (1994) Determinants of the Factor IX Mutational Spectrum in Hemophilia B: An Analysis if Missense Using A Multi-Domain Molecular Model of the Activated Protein. Hum. Genet. 94:594-608.
		Warrier, I. et al., (1995) Safety of High Doses of Monoclonal Antibody Purified Factor IX Concentrate. Am. J. of Hematol. 49:92-94.

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Atty. Docket No. 51917-CB-PCT-US/ JPW/AJM/AAB	Serial No. 10/692,439
	Applicants: David J. Pinsky et al.	
	Filing Date October 22, 2003	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Weyrich et al. (1993) In Vivo Neutralization of P-selectin Protects Feline Heart Endothelium in Myocardial Ishchemia and Reperfusion Injury. J. Clin. Invest. 91:2620-2629.
		Wong, A.G. et al., (1995) Relative Efficacy of Active Site-Blocked Factors IXa in a Model of Venous Thrombosis. Circulation. 92:I-686(Abstract # 3293).
		Wyngaarden et al. Ceril Textbook of Medicine, 19th Edition, Phil.: W.B. Saunders Company, Vol. 2:2376.

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.